Informed Consent
Item
1. written informed consent.
boolean
C0021430 (UMLS CUI [1])
Invasive carcinoma of breast Distant metastasis | Disease Advanced Locally Inoperable
Item
2. proven infiltrating breast cancer with distant metastases or inoperable locally advanced disease.
boolean
C0853879 (UMLS CUI [1,1])
C1269798 (UMLS CUI [1,2])
C0012634 (UMLS CUI [2,1])
C0205179 (UMLS CUI [2,2])
C1517927 (UMLS CUI [2,3])
C0205187 (UMLS CUI [2,4])
Estrogen receptor positive | Nuclei Percentage Positive Immunohistochemistry | Progesterone Known | erbB-2 Receptor Known
Item
3. positive estrogen receptor (≥ 10% positive nuclei at immunohistochemistry). progesterone and her-2 neu receptor have to be known.
boolean
C0279754 (UMLS CUI [1])
C0007610 (UMLS CUI [2,1])
C0439165 (UMLS CUI [2,2])
C1514241 (UMLS CUI [2,3])
C0021044 (UMLS CUI [2,4])
C0033308 (UMLS CUI [3,1])
C0205309 (UMLS CUI [3,2])
C0069515 (UMLS CUI [4,1])
C0205309 (UMLS CUI [4,2])
Progressive Disease | First line Hormone Therapy | Tamoxifen | Aromatase Inhibitors | Neoplasm Metastasis | Disease Advanced Locally Inoperable | LH-RH Agonist allowed | Recurrent disease | Hormone Therapy Adjuvant
Item
4. - progressive disease during first line hormonal therapy (either tamoxifen or aromatase inhibitor) for metastatic or inoperable locally advanced disease. simultaneous use of lh-rh analogs is allowed. or - recurrence of disease (m1) during adjuvant hormonal therapy (either tamoxifen or aromatase inhibitor).
boolean
C1335499 (UMLS CUI [1])
C1708063 (UMLS CUI [2,1])
C0279025 (UMLS CUI [2,2])
C0039286 (UMLS CUI [3])
C0593802 (UMLS CUI [4])
C0027627 (UMLS CUI [5])
C0012634 (UMLS CUI [6,1])
C0205179 (UMLS CUI [6,2])
C1517927 (UMLS CUI [6,3])
C0205187 (UMLS CUI [6,4])
C1518041 (UMLS CUI [7,1])
C0683607 (UMLS CUI [7,2])
C0277556 (UMLS CUI [8])
C0279025 (UMLS CUI [9,1])
C1522673 (UMLS CUI [9,2])
Prior Chemotherapy Absent Neoplasm Metastasis
Item
5. no prior chemotherapy for metastatic disease
boolean
C1514457 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
C0027627 (UMLS CUI [1,3])
Participation Quality of life Investigation
Item
6. willing and able to participate in quality of life investigation -
boolean
C0679823 (UMLS CUI [1,1])
C0034380 (UMLS CUI [1,2])
C1261322 (UMLS CUI [1,3])
Malignant Neoplasms | Exception Carcinoma in Situ | Exception Curative procedure Malignant Neoplasms | Chemotherapy Absent | Therapeutic radiology procedure Absent
Item
1. other malignancy except carcinoma in situ, unless the other malignancy was treated 5 or more years ago with curative intent without the use of chemotherapy or radiation therapy.
boolean
C0006826 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0007099 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C1276305 (UMLS CUI [3,2])
C0006826 (UMLS CUI [3,3])
C0392920 (UMLS CUI [4,1])
C0332197 (UMLS CUI [4,2])
C1522449 (UMLS CUI [5,1])
C0332197 (UMLS CUI [5,2])
Pregnancy | Breast Feeding
Item
2. pregnancy or breast feeding women.
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Medical contraindication capecitabine
Item
3. contra-indications to the use of capecitabine
boolean
C1301624 (UMLS CUI [1,1])
C0671970 (UMLS CUI [1,2])
CNS metastases
Item
4. known cns metastases
boolean
C0686377 (UMLS CUI [1])